We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

87 hedge funds and large institutions have $187M invested in BioSpecifics Technologies Corp. in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 35 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

3% less funds holding

Funds holding: 9087 (-3)

6% less capital invested

Capital invested by funds: $199M → $187M (-$11.3M)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

17% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 35

Holders
87
Holders Change
-3
Holders Change %
-3.33%
% of All Funds
2.17%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
8
Increased
29
Reduced
35
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$19.3M +$790K +16,500 +4%
BlackRock
2
BlackRock
New York
$18M +$217K +4,539 +1%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$12.5M +$186K +3,878 +1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$10.2M +$929K +19,408 +10%
SCM
5
Stonepine Capital Management
Oregon
$9.83M +$7.25M +151,492 +253%
EAM
6
Eagle Asset Management
Florida
$8.81M +$141K +2,936 +2%
ECP
7
Elk Creek Partners
Colorado
$7.91M +$1.18M +24,696 +17%
RHJA
8
Rice Hall James & Associates
California
$7.26M -$264K -5,504 -3%
NC
9
Northpointe Capital
Michigan
$6.31M +$1.25M +26,013 +24%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$5.87M -$1.85M -38,718 -23%
AQR Capital Management
11
AQR Capital Management
Connecticut
$5.44M +$1.18M +24,562 +27%
Goldman Sachs
12
Goldman Sachs
New York
$4.92M -$346K -7,230 -6%
State Street
13
State Street
Massachusetts
$4.43M -$249K -5,201 -5%
Northern Trust
14
Northern Trust
Illinois
$4M +$74.7K +1,561 +2%
Allianz Asset Management
15
Allianz Asset Management
Germany
$3.95M +$13.4K +280 +0.3%
JAM
16
JW Asset Management
Florida
$3.43M
Wellington Management Group
17
Wellington Management Group
Massachusetts
$3.35M
Bank of New York Mellon
18
Bank of New York Mellon
New York
$3.18M +$12.4K +260 +0.4%
Prudential Financial
19
Prudential Financial
New Jersey
$3.13M +$77.6K +1,620 +2%
MCM
20
Matarin Capital Management
New York
$2.75M +$97.8K +2,043 +4%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$2.5M -$168K -3,500 -6%
MOACM
22
Mutual of America Capital Management
New York
$2.46M
Invesco
23
Invesco
Georgia
$2.45M -$11.9K -248 -0.5%
Wells Fargo
24
Wells Fargo
California
$2.1M -$329K -6,879 -13%
OAM
25
Oxford Asset Management
United Kingdom
$2.06M -$544K -11,364 -21%

BSTC Hedge Fund Activity: Q3 2017 in Review

87 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q3 2017, worth a combined $187M — down 5.7% from $199M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of BSTC and 8 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 29 added.

The largest buyer was Stonepine Capital Management, adding an estimated $7.25M. The largest seller was Numeric Investors, cutting an estimated $2.64M.

  • 87 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q3 2017, down from 90 in Q2 2017.
  • Funds reported $187M of BioSpecifics Technologies Corp. stock for Q3 2017, down 5.7% quarter-over-quarter.
  • 8 funds opened new BioSpecifics Technologies Corp. positions in Q3 2017 and 9 closed out, a net change of -1 holder.
  • The largest BioSpecifics Technologies Corp. buyer in Q3 2017 was Stonepine Capital Management, an estimated $7.25M added.
  • The largest BioSpecifics Technologies Corp. seller in Q3 2017 was Numeric Investors, an estimated $2.64M sold.

Based on aggregated 13F filings for Q3 2017.